Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.

This study found that epidermal growth factor significantly enhances the proliferation of hair follicle-derived mesenchymal stem cells through the EGFR/ERK and AKT pathways, without involving the STAT3 pathway.

This study found that downregulation of EGF and KGF signaling is necessary for hair follicle initiation in placodes, revealing a new role for KGF in hair follicle formation in mice.

In a transgenic mouse model, this study found that overexpression of keratin 16 in skin keratinocytes led to hyperkeratosis and increased EGF receptor signaling, altering skin cell behavior and structure.

This case study reported that a 74-year-old woman with metastatic rectal cancer experienced temporary trichomegaly, or eyelash lengthening, associated with cetuximab treatment, which resolved after discontinuation of the drug.

This study reports that eliminating both Trp53 and Rb genes in mouse epidermis accelerates aggressive squamous cell carcinoma development due to early activation of the epidermal growth factor receptor/Akt pathway.

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

In this mouse study, the researchers found that the monoclonal antibody ME1 causes hair follicle inflammation by up-regulating TNFα, which can be reduced by TNFα and interleukin-1 inhibitors.

This study reported that EGFR inhibitor therapy in lung and head/neck cancer patients was associated with acneiform eruptions and severe skin dryness, which rarely necessitate discontinuation of treatment and can be managed symptomatically.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

In this study, a combination of irinotecan and cetuximab showed varied response rates in metastatic colorectal cancer patients, with manageable skin toxicity that improved quality of life when treated collaboratively by oncology and dermatology teams.

This paper discusses the role of epidermal growth factor receptor blockade in altering skin and hair growth, highlighting hair growth stimulation as a potential side effect of cancer therapy; it reports no new experimental results.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

Overexpressing the epigen gene in mice leads to enlarged sebaceous glands and greasy fur.

This study found that locally injected zalutumumab in healthy volunteers induced a papulopustular rash similar to systemic EGFR inhibitors, and that IL-8 inhibition reduced this dermatological side effect.

Erlotinib may cause scarring hair loss.

This review discusses the various skin, mucosa, and adnexa side effects associated with different chemotherapeutic agents and provides insights into their clinical presentation and management; it reports no new results.

This study found that Tideglusib enhances wound healing in aged rats by activating the PI3K/Akt pathway, suggesting its potential for medical and cosmetic applications targeting age-related skin changes.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This study found that in mice lacking EGFR, elevated Wnt signaling disrupts hair follicle development by affecting cell proliferation and differentiation, revealing a critical role for EGFR in regulating these processes.

This study found that the progesterone metabolite 3α-THP increased the proliferation and gene expression of human glioblastoma cells, suggesting a role in tumor progression.

This case report documents a 61-year-old woman treated with erlotinib who experienced the rare side effect of cicatricial alopecia.

This report presents the Taiwanese Dermatological Association's 2016 consensus on defining and managing skin toxicities from EGFR-TKI treatments, providing comprehensive guidelines for clinicians in Taiwan.

Genetic changes in mice help understand skin and hair disorders, aiding treatment development for acne and hair loss.

In this study, the researchers found that constitutive activation of the EGFR in mice led to increased sebum production, enlarged sebaceous glands, and altered gene expression related to sebocyte proliferation and lipogenesis.

This case report describes a 57-year-old Japanese female who developed scarring alopecia linked to gefitinib, an EGFR inhibitor, with improvement in hair loss after reducing the drug dosage.

This study found that inhibiting EGFR signaling in mice can prevent alopecia caused by cyclophosphamide treatment, highlighting its potential role in managing chemotherapy-induced hair loss.

This study describes three cases of acneiform eruptions from EGFR inhibitors that improved with topical recombinant human EGF, suggesting its potential as a treatment option for this side effect.